Abingworth raises $582m to advance late-stage clinical trials
The Abingworth Clinical Co-Development Fund 2 (ACCD 2) has exceeded its target of $350m and closed at the hard cap.…
29 Apr 2021
Pfizer acquires Amplyx Pharmaceuticals to advance anti-infectives pipeline
Pfizer has acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand its anti-infectives pipeline. Amplyx focuses on developing treatments for life-threatening diseases that affect individuals with…
27 Apr 2021
Science park merger creates UK’s largest life sciences ecosystem
US real estate investment company Harrison Street and UK real estate group Trinity Investment Management this week announced their joint acquisition of Nottingham-based science business incubator BioCity. The £120m deal…
23 Apr 2021
Vertex and Obsidian enter agreement to develop gene-editing treatments
Vertex Pharmaceuticals (VRTX) and Obsidian Therapeutics have entered a strategic research partnership and licensing agreement to discover and develop novel therapies that regulate gene editing for treating serious diseases. In…
21 Apr 2021
Janux Therapeutics raises funding to advance T cell engager treatments
Janux Therapeutics has raised $125m through a series B funding round to advance its pipeline of next-generation T cell engager immunotherapies into initial proof of concept (PoC) clinical trials. Led…
19 Apr 2021
AstraZeneca gets US clearance for proposed Alexion acquisition
The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately $39bn or $175 a share. The latest development comes after…
16 Apr 2021
Thermo Fisher to acquire clinical research company PPD for $17.4bn
Thermo Fisher Scientific (TFS) has announced a definitive agreement to acquire clinical research organisation PPD for $47.50 per share for a total consideration of $17.4bn in cash. The company also…
© Copyright Verdict Media Limited 2021
Powered by
